Impel Pharmaceuticals Granted U.S. Patent #11690819: Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's disease
Portfolio Pulse from Charles Gross
Impel Pharmaceuticals has been granted U.S. Patent #11690819 for the respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for the treatment of Parkinson's disease.
July 04, 2023 | 10:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Impel Pharmaceuticals has secured a new patent for a treatment method for Parkinson's disease, which could potentially lead to new revenue streams.
The granting of a new patent to Impel Pharmaceuticals for a treatment method for Parkinson's disease could potentially lead to new revenue streams for the company. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100